United Kingdom Human Growth Hormone Market Insight
The United Kingdom Human Growth Hormone Market is growing at an 11.45% CAGR, driven by rising hormone deficiency cases, NHS access, and adoption of rhGH therapies, with Pfizer Inc. enhancing treatment effectiveness and outcomes
United Kingdom Human Growth Hormone Market Insights Forecasts to 2035
- The United Kingdom Human Growth Hormone Market Size Was Estimated at USD 352.2 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 11.45% from 2025 to 2035
- The United Kingdom Human Growth Hormone Market Size is Expected to Reach USD 1041.45 Million by 2035
Notable Insights for United Kingdom Human Growth Hormone Market
- By product type, recombinant human growth hormone (rhGH) dominated, accounting for approximately 70–75% share in 2024, driven by its effectiveness in treating growth hormone deficiency and related disorders.
- By application, pediatric growth hormone deficiency dominated, holding approximately 55–60% share, due to early diagnosis and increasing treatment adoption among children.
- Approximately 1 in 4,000–10,000 children in the UK are affected by growth hormone deficiency, with increasing diagnosis rates due to improved screening programs.
- The UK accounts for approximately 12–15% of Europe’s human growth hormone market, with over 80% of patients receiving treatment through NHS services, supporting high accessibility.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Human Growth Hormone Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Human Growth Hormone Market
- Pfizer Inc.
- Novo Nordisk
- Eli Lilly and Company
- Merck KGaA
- F. Hoffmann-La Roche Ltd
- Ipsen
- Sandoz
- Teva Pharmaceutical Industries
- Ascendis Pharma
- OPKO Health
- Others
Recent Developments:
- In October 2024: Sogroya (somapacitan) received UK acceptance for pediatric and adult growth hormone deficiency, offering a once-weekly alternative to daily somatropin, improving adherence and long-term treatment outcomes.
- In February 2023: NICE recommended Ngenla (somatrogon) for children aged 3+ with growth hormone deficiency, offering a once-weekly alternative to daily injections, improving adherence and supporting NHS treatment adoption.
Market Segmentation:
United Kingdom Human Growth Hormone Market, By Product Type
- Recombinant Human Growth Hormone (rhGH)
- Biosimilar Growth Hormone
United Kingdom Human Growth Hormone Market, By Application
- Pediatric Growth Hormone Deficiency
- Adult Growth Hormone Deficiency
- Turner Syndrome
- Chronic Kidney Disease
- Others
United Kingdom Human Growth Hormone Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Human Growth Hormone Market is expected to grow steadily due to increasing prevalence of gout and rising demand for long-term disease management solutions. Experts highlight that urate-lowering therapies, biologics, and improved anti-inflammatory treatments will dominate the market. With rising awareness and strong public healthcare support, demand for safe, effective, and long-term gout management solutions is expected to increase, ensuring sustained market growth.